Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Cagrilintide represents a novel approach to obesity management
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
Subscribe To Our Newsletter & Stay Updated
